Page 5 - Lantern Pharma News Today

Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating)’s stock price was up 8% during mid-day trading on Monday . The stock traded as high as $5.85 and last traded at $5.83. Approximately 130,592 shares were traded during mid-day trading, an increase of 304% from the average daily volume of 32,361 shares. The stock had previously closed […]

LP-184 is a novel, synthetically-lethal, small molecule that has been developed using insights from Lantern’s AI platform, RADR®. The first-in-human Phase 1A clinical trial has been... | June 12, 2023

Analysts’ new coverage for Thursday, May 18th: StockNews.com initiated coverage on shares of Agilent Technologies (NYSE:A). The firm issued a buy rating on the stock. StockNews.com assumed coverage on shares of Alcoa (NYSE:AA). They issued a sell rating on the stock. StockNews.com began coverage on shares of American Airlines Group (NASDAQ:AAL). StockNews.com issued a buy […]

Lantern Pharma Inc. , a clinical-stage biopharmaceutical company using its proprietary RADR® artificial intelligence and machine learning platform to transform the cost, pace, and timeline of... | May 17, 2023

Nicole Leber: Good afternoon, everyone. Im Nicole Weber with Investor Relations here at Lantern Pharma. Welcome to our First Quarter 2023 Earnings Call. I will be your host for todays call.

Lantern Pharma Inc. (NASDAQ:LTRN – Get Rating) – Equities researchers at Zacks Small Cap issued their Q2 2023 earnings estimates for Lantern Pharma in a report released on Wednesday, May 10th. Zacks Small Cap analyst J. Vandermosten expects that the company will earn ($0.40) per share for the quarter. The consensus estimate for Lantern Pharma’s […]

Lantern Pharma (NASDAQ:LTRN – Get Rating) will issue its quarterly earnings data after the market closes on Tuesday, May 9th. Parties that are interested in participating in the company’s conference call can do so using this link. Lantern Pharma (NASDAQ:LTRN – Get Rating) last released its earnings results on Monday, March 20th. The company reported […]

BELTSVILLE, Md., May 3, 2023 /PRNewswire/ -- Reprocell USA, a CRO, has been awarded a contract to provide support for Lantern Pharma's Phase 2 clinical trial entitled "A Study of LP-300 With

02.05.2023 - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and ... Seite 1

Dr Kim discusses the evaluation of LP-300 for the treatment of patients with advanced lung adenocarcinoma, the rationale for exploring this agent in combination with chemotherapy, and the ongoing HARMONIC trial investigating the combination of LP-300 plus carboplatin and pemetrexed.